导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.72% | 3164/4773 |
| 近一周 | -1.87% | 809/5462 |
| 近一月 | -1.95% | 1096/5421 |
| 近一季 | -1.70% | 1052/5209 |
| 近半年 | -1.54% | 1626/4920 |
| 近一年 | -0.95% | 2804/4366 |
| 近两年 | 31.53% | 2216/2954 |
| 近三年 | 19.24% | 1494/2253 |
| 成立以来 | 30.79% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.31% 4092/4961 |
6.62% 2813/5312 |
- - |
- - |
| 2025 | 15.16% 2566/4813 |
-0.60% 2319/3635 |
2.66% 1444/4076 |
10.69% 3257/4524 |
1.96% 1130/4813 |
| 2024 | 15.42% 931/3463 |
3.37% 586/2808 |
-0.12% 684/3014 |
16.05% 1554/3129 |
-3.67% 2377/3463 |
| 2023 | -8.30% 998/2656 |
0.84% 1688/2280 |
-4.27% 1120/2385 |
1.66% 294/2515 |
-6.56% 1827/2655 |
| 2022 | -16.18% 458/2207 |
-10.99% 468/1919 |
6.56% 669/2016 |
-12.84% 794/2113 |
1.40% 1282/2208 |
| 2021 | -5.03% 969/1822 |
-2.26% 610/1255 |
1.54% 1047/1330 |
-6.37% 922/1466 |
2.20% 660/1822 |
| 2020 | 30.92% 513/1250 |
-8.32% 599/1028 |
12.16% 697/1067 |
13.20% 341/1164 |
12.47% 462/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.60% 700/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达上证50ETF联接基金C VS. 长安沪深300非周期A(740101) |